{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=14", "query": { "intervention": "5-Fluorouracil (5FU)", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1004, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T05:28:06.577Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02997228", "title": "Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2018-01-19", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 445, "location_summary": "Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02997228" }, { "nct_id": "NCT00507585", "title": "Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Avastin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 63, "start_date": "2006-06", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507585" }, { "nct_id": "NCT01446458", "title": "Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of Pancreas", "Cancer of the Pancreas", "Neoplasms, Pancreatic", "Pancreas Cancer", "Pancreas Neoplasms" ], "interventions": [ { "name": "Modified FOLFIRINOX", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 13, "start_date": "2011-11", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446458" }, { "nct_id": "NCT01747551", "title": "FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ziv-aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-01", "completion_date": "2017-07-26", "has_results": true, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747551" }, { "nct_id": "NCT00004257", "title": "Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Albany Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004257" }, { "nct_id": "NCT01489865", "title": "ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ABT-888", "type": "DRUG" }, { "name": "mFOLFOX-6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2011-01-03", "completion_date": "2023-12-07", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489865" }, { "nct_id": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Givastomig", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-02-11", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 3, "location_summary": "Goodyear, Arizona • Duarte, California • Boston, Massachusetts", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07432295" }, { "nct_id": "NCT05379595", "title": "A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Amivantamab IV", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "BIOLOGICAL" }, { "name": "Amivantamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2022-07-29", "completion_date": "2031-05-11", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05379595" }, { "nct_id": "NCT07603375", "title": "Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2034-02", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07603375" }, { "nct_id": "NCT02620865", "title": "BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Antibody Therapy", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2015-12", "completion_date": "2021-06-21", "has_results": true, "last_update_posted_date": "2023-05-15", "last_synced_at": "2026-10-14T05:28:06.577Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620865" } ] }